Anti-pan Cytokeratin antibody [AE1/AE3] (ab27988)

Publishing research using ab27988? Please let us know so that we can cite the reference in this datasheet.

ab27988 has been referenced in 7 publications.

  • Crowley C  et al. Surface modification of a POSS-nanocomposite material to enhance cellular integration of a synthetic bioscaffold. Biomaterials 83:283-93 (2016). IHC-P ; Human . PubMed: 26790147
  • Rydell-Törmänen K  et al. Aberrant nonfibrotic parenchyma in idiopathic pulmonary fibrosis is correlated with decreased ß-catenin inhibition and increased Wnt5a/b interaction. Physiol Rep 4:N/A (2016). IHC-P ; Human . PubMed: 26997628
  • Trembley JH  et al. Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice. PLoS One 9:e109970 (2014). PubMed: 25333839
  • Coughlan L  et al. Combined fiber modifications both to target a(v)ß(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Hum Gene Ther 23:960-79 (2012). IHC-P ; Mouse . PubMed: 22708837
  • He S  et al. Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro. Invest Ophthalmol Vis Sci 51:543-52 (2010). PubMed: 19696168
  • Zitzmann-Kolbe S  et al. D-18F-fluoromethyl tyrosine imaging of bone metastases in a mouse model. J Nucl Med 51:1632-6 (2010). IHC ; Mouse . PubMed: 20847178
  • Listrom MB & Dalton LW Comparison of keratin monoclonal antibodies MAK-6, AE1:AE3, and CAM-5.2. Am J Clin Pathol 88:297-301 (1987). PubMed: 2443001

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"